Date: Nov 12, 2015 Source: Business Wire (
click here to go to the source)
BALTIMORE--(BUSINESS WIRE)--Cerecor Inc. (NASDAQ: CERCU), a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders, today announced that the units issued in Cerecor's recent initial public offering will separate on November 13, 2015. Each unit consists of one share of common stock of Cerecor, one Class A warrant to purchase one additional share of common stock of Cerecor and one Class B warrant to purchase one-half additional share of common stock of Cerecor.
At the commencement of trading on November 13th, 2015, the common stock, the Class A warrants and the Class B warrants will trade separately on The NASDAQ Capital Market under the symbols "CERC", "CERCW" and "CERCZ", respectively. The units, which are currently traded under the symbol "CERCU", will no longer be listed on The NASDAQ Capital Market following the separation.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
About Cerecor
Cerecor Inc. is a Baltimore-based biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases by addressing the unmet medical needs of underserved patient segments. We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders.
